AU2018284330B2 - Treatment for migraine - Google Patents

Treatment for migraine Download PDF

Info

Publication number
AU2018284330B2
AU2018284330B2 AU2018284330A AU2018284330A AU2018284330B2 AU 2018284330 B2 AU2018284330 B2 AU 2018284330B2 AU 2018284330 A AU2018284330 A AU 2018284330A AU 2018284330 A AU2018284330 A AU 2018284330A AU 2018284330 B2 AU2018284330 B2 AU 2018284330B2
Authority
AU
Australia
Prior art keywords
leucine
acetyl
migraine
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018284330A
Other languages
English (en)
Other versions
AU2018284330A1 (en
Inventor
Mallory Factor
Michael Strupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018284330(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of AU2018284330A1 publication Critical patent/AU2018284330A1/en
Application granted granted Critical
Publication of AU2018284330B2 publication Critical patent/AU2018284330B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018284330A 2017-06-14 2018-06-25 Treatment for migraine Active AU2018284330B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1709459.0 2017-06-14
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
AU2018284330A1 AU2018284330A1 (en) 2020-01-02
AU2018284330B2 true AU2018284330B2 (en) 2024-03-14

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018284330A Active AU2018284330B2 (en) 2017-06-14 2018-06-25 Treatment for migraine

Country Status (25)

Country Link
US (1) US11471434B2 (enExample)
EP (1) EP3638370B1 (enExample)
JP (1) JP7130739B2 (enExample)
KR (1) KR102594130B1 (enExample)
CN (1) CN111093772B (enExample)
AU (1) AU2018284330B2 (enExample)
CY (1) CY1123860T1 (enExample)
DK (1) DK3638370T3 (enExample)
ES (1) ES2847169T3 (enExample)
GB (1) GB201709459D0 (enExample)
HR (1) HRP20210108T1 (enExample)
HU (1) HUE053089T2 (enExample)
IL (1) IL271211B2 (enExample)
LT (1) LT3638370T (enExample)
MA (1) MA49396B1 (enExample)
MD (1) MD3638370T2 (enExample)
MX (1) MX387909B (enExample)
PL (1) PL3638370T3 (enExample)
PT (1) PT3638370T (enExample)
RS (1) RS61481B1 (enExample)
SG (1) SG11201912146RA (enExample)
SI (1) SI3638370T1 (enExample)
SM (1) SMT202100037T1 (enExample)
WO (1) WO2018229738A1 (enExample)
ZA (1) ZA201908087B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221886B2 (en) * 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1641775B1 (en) * 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
CN1856484B (zh) * 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
JP4634385B2 (ja) * 2003-09-22 2011-02-16 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用なフェニル−カルボキサミド化合物
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004019576D1 (de) * 2003-12-30 2009-04-02 Euro Celtique Sa Zur behandlung von schmerzen geeignete piperazine
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
ES2732818T3 (es) * 2010-11-09 2019-11-26 Mannkind Corp Composición que comprende un agonista de receptores de serotonina y una dicetopiperazina para tratar migrañas
WO2013021276A1 (en) * 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
MA43876B1 (fr) 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3600276T (lt) 2017-03-28 2023-08-10 Intrabio Ltd Betahistinas arba farmaciniu požiūriu priimtina jo druska ir monoaminooksidazės inhibitorius, skirti panaudoti subjekto gydymui arba profilaktikai vieno arba daugiau vestibulinio galvos svaigimo simptomų
RU2763425C2 (ru) 2017-10-18 2021-12-29 Интрабио Лимитед Терапевтические агенты для нейродегенеративных заболеваний
WO2019079536A1 (en) 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
AU2019221886B2 (en) 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
SI3934637T1 (sl) 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
PL3989962T3 (pl) 2019-06-28 2025-11-17 Intrabio Ltd Terapia skojarzona acetyloleucyną i miglustatem w leczeniu lizosomalnej choroby spichrzeniowej
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Also Published As

Publication number Publication date
PL3638370T3 (pl) 2021-05-17
KR20210013518A (ko) 2021-02-04
SMT202100037T1 (it) 2021-03-15
ES2847169T3 (es) 2021-08-02
DK3638370T3 (da) 2021-01-25
US20200253905A1 (en) 2020-08-13
CN111093772A (zh) 2020-05-01
CN111093772B (zh) 2023-11-03
ZA201908087B (en) 2024-11-27
SI3638370T1 (sl) 2021-04-30
CY1123860T1 (el) 2022-05-27
WO2018229738A1 (en) 2018-12-20
IL271211B1 (en) 2023-09-01
MA49396B1 (fr) 2021-03-31
RU2020100475A (ru) 2021-07-14
KR102594130B1 (ko) 2023-10-24
JP7130739B2 (ja) 2022-09-05
CA3067321A1 (en) 2018-12-20
MD3638370T2 (ro) 2021-04-30
HRP20210108T1 (hr) 2021-03-19
EP3638370B1 (en) 2020-11-11
EP3638370A1 (en) 2020-04-22
JP2020526575A (ja) 2020-08-31
US11471434B2 (en) 2022-10-18
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396A (fr) 2020-04-22
RU2020100475A3 (enExample) 2021-10-22
MX2019014784A (es) 2021-11-16
AU2018284330A1 (en) 2020-01-02
HUE053089T2 (hu) 2021-06-28
SG11201912146RA (en) 2020-01-30
PT3638370T (pt) 2021-01-26
RS61481B1 (sr) 2021-03-31
LT3638370T (lt) 2021-03-25
GB201709459D0 (en) 2017-07-26
IL271211B2 (en) 2024-01-01
IL271211A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
KR102791288B1 (ko) 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
US20210353559A1 (en) Composition and method for treating neurological disease
AU2018284330B2 (en) Treatment for migraine
US10512617B2 (en) Composition and method for treating neurological disease
US11833121B2 (en) Composition and method for treating neurological disease
CA3067321C (en) Use of acetyle-leucine to prevent and/or treat migraine
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
RU2772278C2 (ru) Лечение мигрени
HK40023292A (en) Treatment of migraine with acetyl-leucine
HK40023292B (en) Treatment of migraine with acetyl-leucine
KR20070083903A (ko) 경구 효과적인 칸나비노이드 유사체
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
AU2012391533B2 (en) Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
JP2024505283A (ja) 遂行機能障害の処置のための併用療法